Throne Biotechnologies

Throne Biotechnologies

Find a cure type 1 diabetes, alopecia areata, and other autoimmune diseas...

Claim My Business
Security Type
Common Stock
Healthcare & Medical
Min Investment
Paramus, NJ
Offering Date
March 03, 2022
Expected Close Date
April 30, 2022
Target Raise
No. Investors
Security Price
Number of Employees
Short Term Debt
Cost of Goods
Long Term Debt
Net Income

Company Description

Throne offers the Practical Cure for type 1 diabetes, alopecia areata, and other autoimmune diseases through its patented technology, Stem Cell Educator therapy — a one-time, dialysis-like treatment that fundamentally “re-educates” the defective immune system back to health. Throne is in the pre-revenue clinical stage of development.


StartEngine OWNERS Exclusive Click here to learn more

$349+ Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

$1,000+ Investment
Level 1
Invest $1,000 and receive an additional 10% bonus shares

$2,500+ Investment
Level 2
Invest $2,500 and receive an additional 11% bonus shares

$5,000+ Investment
Level 3
Invest $5,000 and receive an additional 12% bonus shares + A patient of your choice will secure 'Tier 5 Priority' on the treatment waiting list for receiving the Stem Cell Educator Therapy upon commercialization in the US*

$10,000+ Investment
Level 4
Invest $10,000 and receive an additional 13% bonus shares + A patient of your choice will secure 'Tier 4 Preferential Priority' on the treatment waiting list for receiving the Stem Cell Educator Therapy upon commercialization in the US*

$25,000+ Investment
Level 5: Invest $25,000, receive 14% bonus shares
A patient of your choice will secure 'Tier 3 Premium Priority' on the treatment waiting list for receiving the Stem Cell Educator Therapy upon commercialization in the US*
+ $1,000 off of commercial treatment price (if paid for out of pocket)

$50,000+ Investment
Level 6: Invest $50,000, receive 15% bonus
Additionally, Patient you choose will secure 'Tier 2 Top Priority' on the treatment waiting list for receiving the Stem Cell Educator Therapy upon commercialization in the US* + $3,000 off of commercial treatment price (if paid for out of pocket)

$100,000+ Investment
Level 7: Invest $100,000, receive 15% bonus shares
Patient you choose gets Tier 1 Super Priority for treatment wait list for Stem Cell Educator Therapy upon commercialization in US**, $5,000 off treatment price (if paid out of pocket), In person lunch with Throne Execs for you and 2 guests in NJ***

Key Deal Facts

Throne Has a Globally-Leading Curative Patent Technology for Type 1 Diabetes (T1D) and Other Autoimmune Diseases: Over last 10 years, international multicenter clinical trials in the United States, China, and Spain have strongly demonstrated the clinical safety and efficacy of Stem Cell Educator therapy in more than 200 patients aged from 3 to 70 years old. Clinical studies and basic research revealed the molecular and cellular mechanisms underlying Stem Cell Educator therapy with over 30 peer-reviewed publications. Collectively, Educator therapy has the potential to revolutionize the treatment of T1D and other autoimmune diseases, without the safety and ethical concerns associated with conventional immune and/or stem cell-based approaches.

Experienced Team: Throne Biotechnologies (Throne) is a clinical-stage therapeutic company with a disruptive stem cell technology that can, for some patients, fundamentally reverse T1D and other autoimmune diseases. To commercialize the Stem Cell Educator therapy, Throne has built up the strong Team with renowned scientists, immunologist, endocrinologist, diabetologist, dermatologist, expert in cellular therapy, and entrepreneurs from big pharmaceutical/biotech companies and famous universities.

It Is Close to the US FDA Marketing Approval through Regenerative Medicine Advanced Therapy (RMAT) Program: Currently, Stem Cell Educator therapy has gained three phase 2 clinical trial approvals by the United States FDA to treat T1D, alopecia areata and severe COVID-19 patients. As a global-leading technology in the field of T1D treatment (Juvenile Diabetes Cure Alliance Report, 2021, New York), it is highly expected that Educator therapy will achieve the expedited FDA approval for commercialization under the designation of RMAT, due to an unmet medical need for the T1D and alopecia patients. The T1D market in 2019 was approximately $2 billion and is expected to grow at a 5% CAGR (Compound Annual Growth Rate). The Alopecia market in 2020 was approximately $7.6 billion and is expected to grow at an 8.1% CAGR.

Management Team / Advisory Board Bios

Theodore Mazzone, MD

Chief Medical Officer

Dr. Mazzone is a renowned endocrinologist and diabetologist with 40 years of experience as a clinical physician, professor, and scientist with over 135 publications; He was the Chairman of the Department of Medicine at the Northshore University Health of the University of Chicago, a tenured Professor of Medicine at Rush University Medical Center, and is the Founder and Director of University of Illinois at Chicago’s Center for Clinical and Translational Science. He was named “Castle Connolly’s America’s Top Doctors” and received his MD from the Northwestern University Medical School.

Gerald Ostrov, MBA

Board Director

Mr. Ostrov had first-hand experience of the efficacy of Throne’s technology through the treatment of his 13 year old grandson for type 1 diabetes. He was the former Company Group Chairman of Johnson & Johnson’s North America Consumer and Personal Care businesses. He was also the President of CIBA Consumer Pharmaceutical (now Novartis), Company Group Chairman for Johnson & Johnson’s Worldwide Vision Care businesses, and Chairman and CEO of Bausch and Lomb. He received his MBA from Harvard University. 

Lee Dudka, PhD

Board Director

Dr. Dudka has been a lifelong healthcare industry veteran including roles as an executive strategy consultant for Bristol Myers Squibb, Johnson & Johnson, & Pfizer. He was a fellow at the National Institute of Health and was the President of American College of Neuropsychopharmacology. He was a Professor at Princeton, Rutgers, and State University of New York. His expertise is in full operations-to-market drug launches, HIT and healthcare reengineering. He helps C-level executives and teams create strategic impact while tackling operations/market hurdles. He holds a PhD from Princeton University.

Henry Lozano

VP Global Relations

Mr. Lozano is a business executive with diplomatic correspondence to national and international heads of state for the top-down adoption of health and social services. His years of public service culminated in his post at the White House as Deputy Assistant to the President and Director of USA Freedom Corps. He was the Deputy Assistant to the President of the United States and a bi-partisan senior member of the White House under 5 presidents including George H. W. Bush and Barack Obama; He was appointed Director of USA Freedom Corps and received the Presidential Call to Service Award.

Brett King, MD, PhD

Principal Investigator - Alopecia Areata Trial

Dr. King is an Associate Professor of Dermatology at Yale University School of Medicine, specializing in skin inflammatory and autoimmune skin diseases recalcitrant to first-line therapies. He has pioneered the use of Janus kinase (JAK) inhibitors in cutaneous diseases, in particular for alopecia areata and other cutaneous diseases. Dr. King received his B.A. at the University of California, his Ph.D. from Stanford University and his M.D. from Yale University School of Medicine. He completed medical internship at Massachusetts General Hospital and dermatology residency at Yale University School of Medicine.

Colette Knight, MD

Principal Investigator - Type 1 Diabetes Trial

Dr. Knight is specialized expert in field of diabetes, endocrinology, and metabolism; SHe is the Chair of Hackensack University’s Medical Center’s Diabetes Institute and Division Director of Endocrinology and Metabolism in the Department of Internal Medicine; She received her Fellowship in endocrinology at Albert Einstein College of Medicine & Montefiore Medical Center, and his MD from Harvard Medical School 

Edward Ludwig, MBA

Business Advisor

Mr. Ludwig accomplished healthcare veteran with special personal interests in a diabetes cure; He is the former chairman of the board of Becton, Dickinson and Company (also known as BD), a global medical technology company, having served in that position from 2002 through 2012. He also served as BD’s chief executive officer (CEO) from January 2000 to September 2011 and as its president from May 1999 to December 2008. He is a Senior auditor at PWC; Board Director of CVS Health; Board of trustees at Hackensack University Medical Center; He received his MBA from Columbia University.

Rona Weinberg, PhD

Scientific Advisor

Rona has 20+ year Director of the Cellular Therapy Laboratory at New York Blood Center with specializations in developing stem cell, gene therapy, and immunotherapy products; She is an Associate Member of the Lindsley F. Kimball Research Institute, and the Head of Myeloproliferative Disorders (MPD) Research Laboratory; She received her PhD and Post-doctoral training from Mount Sinai School of Medicine in New York.

Yechin Zhao, MBA

Director of Business Development

Mr. Zhao is an experienced entrepreneur with track-record of global successes in innovation development. He has a special focus on pediatric-centered healthcare; He is the founder of Skipper Yacht-share and was an innovation & marketing consultant on projects with Fortune 100 clients including McDonald’s, Disney, and Google. His MBA is from the University of Illinois Urbana-Champaign (UIUC).
Amount Raised : $184,041
Reveal the Score by Voting
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.

Security Description

Common stock is a security that represents ownership in a corporation.

Research Reports

No reports have been submitted

Become a Reporter